Clinical Trials
The Phase III study’s principal investigator said that if Xpovio doesn’t win approval, NCCN Guidelines could enable off-label use, as has occurred with BMS’s Reblozyl.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Henlius is advancing its nivolumab biosimilar HLX18 into Chinese trials, as it expands a global oncology pipeline. In 2025, the firm’s strong revenue growth was offset by rising R&D investment amid increasing contributions from overseas partnerships.
Dizal's Zegfrovy (sunvozertinib), already approved in the US and China for the second-line treatment of NSCLC with EGFR exon 20 insertion mutations, triumphs in the WU-KONG28 Phase III study in the first-line setting.
The first multinational clinical trial approval under the EU’s 70‑day fast-track pilot pathway is expected by the end of April 2026.
Kintor's topical androgen receptor inhibitor KX-826 posts win in China Phase III trial in male androgenetic alopecia, following a Phase III setback in 2023.
Spanish firm's CSO Karl Ziegelbauer shares with Scrip his views on potential alliances with Chinese and other companies and what Almirall can bring to the table.
The drugmaker announced that its Phase II trial of atirmociclib, a CDK4 inhibitor, succeeded in patients who had progressed on CDK4/6 inhibitors and had better tolerability than the earlier class.
The company announced Phase I data for varsetatug masetecan in metastatic colorectal cancer, where it sees a significant and largely untapped market.
EU data protection bodies back clinical trial harmonization under the draft Biotech Act, but insist on strong safeguards for sensitive health data.
The mineralocorticoid receptor antagonist, which will be a key driver at the German group in the post-Xarelto world, significantly delayed kidney disease progression in non-diabetic patients in another successful late-stage trial.
A new survey of French healthcare professionals reveals concerns that France is increasingly being excluded from major international clinical studies.